Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
TUBERCULOSIS PIPELINE ANALYSIS
• Tuberculosis is considered a chronic infectious disease caused by a bacterium called Mycobacterium tuberculosis and is a highly contagious disease
• . This bacterium is present in the air and is communicable. It occurs by inhaling tuberculosis bacilli in the air. It usually affects the lungs (pulmonary tuberculosis) and can also target other body parts, including the spine, brain, and kidney.
• The bacterial infection spreads through lymph nodes, bloodstream to any organ in the body. Mainly tuberculosis is of two types including latent tuberculosis and active tuberculosis. In latent TB condition, the person infected with the bacteria but it is in an active state and causes no symptoms.
• It isn’t contagious and also called inactive tuberculosis (or) TB but can turn into active TB. Thus treatment is important for latent TB and for controlling the spread of TB.
• Active Tuberculosis stage enables bacteria spread to others. It may occur in initial stages of infection with the Mycobacterium tuberculosis bacteria, or it might occur years later.
• The development pipeline was remained thin, but for the first time in decades, multiple drugs are found in the clinical development of tuberculosis. Some discovery efforts are directed towards designing drugs that retain potent anti-TB activity but showing fewer undesirable attributes including water-soluble analogs of clofaziminethat are less likely to cause skin discoloration or oxazolidinones showing less mitochondrial toxicity and reduced risk of dose-limiting neuropathy compared with linezolid. Several new chemical entities have progressed to clinical evaluation, including nitroimidazoles (delamanid, PA-824, and TBA-354), oxazolidinones (sutezolid and AZD5847), the ATP synthase inhibitor, bedaquiline and an ethambutol analog, SQ109. Bedaquiline was registered with the Food and Drug Administration after expedited review and is available for treatment of multi-drug-resistant tuberculosis (MDR-TB) in some settings.
• Efforts to optimize rifamycin antibiotics (rifampin and rifapentine) or repurpose drugs showing good anti-TB activity (moxifloxacin) are under study, and these drugs are considered as a part of the tuberculosis drug pipeline.
• TB Alliance in conjunction with Janssen Pharmaceuticals is conducting Nix-TB trial that involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which is definitely used as a cure for Extensively Drug Resistant (XDR) form of the disease.
• Dishman Group has received a license agreement from Janssen Pharmaceutica, (a subsidiary of J&J) to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline).
• The drugs that are under phase III clinical trial development include Bedaquiline, FS-1, Delamanid, Isoniazid, Rifapentine, Moxifloxacin, Rifampin, Linezolid, Tenofovir, Lamivudine, and others, which are going to add the growth for the tuberculosis global market.
• The driving factors of the TB market include a rise in the number of tuberculosis patients, increasing awareness among people, and the increasing number of research and development activities in developing novel drugs.
• Moreover, technological advancement in early stage detection, and government & non-government organizations initiating the promotion of tuberculosis drugs are further leading to TB market growth. Anyway, some of the adverse drug reactions to the people may inhibit the tuberculosis market growth.
• Tuberculosis is considered a chronic infectious disease caused by a bacterium called Mycobacterium tuberculosis and is a highly contagious disease
• . This bacterium is present in the air and is communicable. It occurs by inhaling tuberculosis bacilli in the air. It usually affects the lungs (pulmonary tuberculosis) and can also target other body parts, including the spine, brain, and kidney.
• The bacterial infection spreads through lymph nodes, bloodstream to any organ in the body. Mainly tuberculosis is of two types including latent tuberculosis and active tuberculosis. In latent TB condition, the person infected with the bacteria but it is in an active state and causes no symptoms.
• It isn’t contagious and also called inactive tuberculosis (or) TB but can turn into active TB. Thus treatment is important for latent TB and for controlling the spread of TB.
• Active Tuberculosis stage enables bacteria spread to others. It may occur in initial stages of infection with the Mycobacterium tuberculosis bacteria, or it might occur years later.
• The development pipeline was remained thin, but for the first time in decades, multiple drugs are found in the clinical development of tuberculosis. Some discovery efforts are directed towards designing drugs that retain potent anti-TB activity but showing fewer undesirable attributes including water-soluble analogs of clofaziminethat are less likely to cause skin discoloration or oxazolidinones showing less mitochondrial toxicity and reduced risk of dose-limiting neuropathy compared with linezolid. Several new chemical entities have progressed to clinical evaluation, including nitroimidazoles (delamanid, PA-824, and TBA-354), oxazolidinones (sutezolid and AZD5847), the ATP synthase inhibitor, bedaquiline and an ethambutol analog, SQ109. Bedaquiline was registered with the Food and Drug Administration after expedited review and is available for treatment of multi-drug-resistant tuberculosis (MDR-TB) in some settings.
• Efforts to optimize rifamycin antibiotics (rifampin and rifapentine) or repurpose drugs showing good anti-TB activity (moxifloxacin) are under study, and these drugs are considered as a part of the tuberculosis drug pipeline.
• TB Alliance in conjunction with Janssen Pharmaceuticals is conducting Nix-TB trial that involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which is definitely used as a cure for Extensively Drug Resistant (XDR) form of the disease.
• Dishman Group has received a license agreement from Janssen Pharmaceutica, (a subsidiary of J&J) to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline).
• The drugs that are under phase III clinical trial development include Bedaquiline, FS-1, Delamanid, Isoniazid, Rifapentine, Moxifloxacin, Rifampin, Linezolid, Tenofovir, Lamivudine, and others, which are going to add the growth for the tuberculosis global market.
• The driving factors of the TB market include a rise in the number of tuberculosis patients, increasing awareness among people, and the increasing number of research and development activities in developing novel drugs.
• Moreover, technological advancement in early stage detection, and government & non-government organizations initiating the promotion of tuberculosis drugs are further leading to TB market growth. Anyway, some of the adverse drug reactions to the people may inhibit the tuberculosis market growth.
